Meeting
2019 ASCO Annual Meeting
Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.
Authors
Inna Y. Gong
Department of Medicine, University of Toronto, Toronto, ON, Canada
Inna Y. Gong , Andrew T Yan , Maureen E. Trudeau , Andrea Eisen , Craig Earle , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1037)
DOI
10.1200/JCO.2019.37.15_suppl.1037
Abstract #
1037
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
First Author: Daniel M. Geynisman
Poster
2020 ASCO Virtual Scientific Program
Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab and trastuzumab for HER2-positive metastatic breast cancer in a real-life cohort.
First Author: Laetitia Collet
Poster
2019 ASCO Annual Meeting
Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
First Author: Abby Statler
Poster
2017 ASCO Quality Care Symposium
The use of real-world data to examine comparative effectiveness research (CER) and treatment patterns in HER2-negative and triple-negative metastatic breast cancer (MBC): A systematic literature review.
First Author: Monika Parisi